Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men

Diabetologia

Volumn 51, Issue 7, 2008, Pages 1135-1145

  Lewitt, M S ^a   Hilding, A ^a   Ostenson C G ^a   Efendic, S ^a   Brismar, K ^a   Hall, K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes prediction; Hepatic insulin resistance; Impaired fasting glucose; Impaired glucose tolerance; Insulin like growth factor binding protein 1; Insulin like growth factor I; Type 2 diabetes

Indexed keywords

GLUCOSE; PROINSULIN; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; ALGORITHM; ARTICLE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADULT; BLOOD GLUCOSE; BODY HEIGHT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROINSULIN; PROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; WAIST-HIP RATIO;

EID: 44749084649     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-1016-x     Document Type: Article

References (50)

1. Suikkari A-M, Koivisto VA, Koistinen R, Seppälä M, Yki-Järvinen H (1989) Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab 68:135-140
2. Conover CA, Lee PDK, Kanaley JA, Clarkson JT, Jenson MD (1992) Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 74:1355-1360
3. Lee PDK, Jensen MD, Divertie GD, Heiling VJ, Katz HH, Conover CA (1993) Insulin-like growth factor-binding protein-1 response to insulin during suppression of endogenous insulin secretion. Metabolism 42:409-414
4. Hilding A, Möller C, Hall KE (2002) Glucagon and GLP-1 stimulate IGFBP-1 secretion in Hep G2 cells without effect on IGFBP-1 mRNA. Growth Horm IGF Res 12:60-68
5. Samstien B, Hoimes ML, Fan J, Frost RA, Gelato MC, Lang CH (1996) IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. Biochem Biophys Res Commun 228:611-615
6. Lang CH, Nystrom GJ, Frost RA (1999) Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species. Am J Physiol 276:G719-G727
7. Lewitt MS, Baxter RC (1991) Insulin-like growth factor-binding protein-1: a role in glucose counterregulation? Mol Cell Endocrinol 79:C147-C152
8. Bar RS, Boes M, Clemmons DR et al (1990) Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology 127:497-499
9. Wang J, Shafqat J, Hall K et al (2006) Specific cleavage of insulin-like growth factor-binding protein-1 by a novel protease activity. Cell Mol Life Sci 63:2405-2414
10. Heald AH, Cruickshank JK, Riste LK et al (2001) Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44:333-339
11. Heald AH, Siddals KW, Fraser W et al (2002) Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 51:2629-2636
12. Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K (2003) C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 170:79-86
13. Kalme T, Seppala M, Qiao Q et al (2005) Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 90:1550-1556
14. Rajpathak SN, McGinn AP, Strickler HD et al (2008) Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 18:166-173
15. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 89:114-120
16. Qiu C, Vadachkoria S, Meryman L, Frederick IO, Williams MA (2005) Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus. Am J Obstet Gynecol 193:1691-1697
17. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359:1740-1745
18. Barrett-Connor E, Ferrara A (1998) Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 21:1236-1239
19. Singleton JR, Smith AG, Russell JW, Feldman EL (2003) Microvascular complications of impaired glucose tolerance. Diabetes 52:2867-2873
20. Kuhl J, Hilding A, Ostenson CG, Grill V, Efendic S, Bavenholm P (2005) Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity. Diabetologia 48:35-40
21. Hilding A, Eriksson AK, Agardh EE et al (2006) The impact of family history of diabetes and lifestyle factors on abnormal glucose regulation in middle-aged Swedish men and women. Diabetologia 49:2589-2598
22. Grill V, Dinesen B, Carlsson S, Efendic S, Pedersen O, Ostenson CG (2002) Hyperproinsulinemia and proinsulin-to-insulin ratios in Swedish middle-aged men: association with glycemia and insulin resistance but not with family history of diabetes. Am J Epidemiol 155:834-841
23. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. WHO, Geneva
24. Póvoa G, Roovete A, Hall K (1984) Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 107:563-570
25. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124:620-629
26. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375-1384
27. Hadaegh F, Zabetian A, Harati H, Azizi F (2006) Waist/height ratio as a better predictor of type 2 diabetes compared to body mass index in Tehranian adult men-a 3.6-year prospective study. Exp Clin Endocrinol Diabetes 114:310-315
28. Ohlson LO, Larsson B, Bjorntorp P et al (1988) Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31:798-805
29. Dinneen S, Maldonado D, Leibson C et al (1998) Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 21:1408-1413
30. Bjørnholt JV, Erikssen G, Liestølt K, Jervell J, Erikssen J, Thaulow E (2001) Prediction of type 2 diabetes in healthy middle aged men with special emphasis on glucose homeostasis. Results from 22.5 years' follow-up. Diabet Med 18:261-267
31. Lyssenko V, Almgren P, Anevski D et al (2005) Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54:166-174
32. Mogul HR, Marshall M, Frey M et al (1996) Insulin-like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 81:4492-4495
33. Liew CF, Wise SD, Yeo KP, Lee KO (2005) Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men. J Clin Endocrinol Metab 90:1483-1488
34. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, Yudkin JS (1999) Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol 50:221-228
35. Kamoda T, Saitoh H, Inudoh M, Miyazaki K, Matsui A (2006) The serum levels of proinsulin and their relationship with IGFBP-1 in obese children. Diabetes Obes Metab 8:192-196
36. Wareham NJ, Byrne CD, Williams R, Day NE, Hales CN (1999) Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 22:262-270
37. Lewitt MS, Hall K, Bang P, Brismar K (2005) Altered response of IGFBP-1 to nutritional deprivation in type 2 diabetes mellitus. Metabolism 54:275-280
38. Båvenholm PN, Pigon J, Östensson C-G, Efendic S (2001) Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 50:1449-1454
39. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293:E1709-E1715
40. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K (1995) Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 80:2646-2652
41. Hilding A, Brismar K, Thorén M, Hall K (1993) Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1142-1147
42. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405
43. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054
44. Qiao Q, Tuomilehto J, Borch-Johnsen K (2003) Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46(Suppl 1):M17-M21
45. Janssen JAMJL, Stolk RP, Pols H, Grobbee DE, Lamberts SWJ (1998) Serum total IGF-I, free IGF-I, and IGFBP-1 levels in an elderly population-relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 18:277-282
46. Harrela M, Koistinen R, Tuomilehto J, Nissinen A, Seppälä M (2000) Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med 32:424-428
47. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106:939-944
48. Brismar K, Lewitt MS (2005) The IGF system in insulin resistance and diabetes mellitus. In: Houston MS, Holly J, Feldman E (eds) Nutrition and the IGF system. Humana, Totowa, NJ, pp 251-270
49. Rajkumar K, Barron D, Lewitt MS, Murphy LJ (1995) Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 136:4029-4034
50. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC (1991) Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129:2254-2256